UAB research: Preventing deaths from Herpes
"Herpes simplex virus infections that reach the central nervous system are a significant cause of mortality particularly among newborns. While use of acyclovir has improved outcomes, the number of fatalities and cases of permanent neurologic impairment is unacceptably high," said Debra C. Quenelle, PhD, Associate Professor, the University of Alabama at Birmingham School of Medicine. "CMX001 has demonstrated improved efficacy to acyclovir in reducing viral load and reducing viral replication, particularly in the CNS, in studies of Herpes Simplex Virus (HSV) infected mice which have been highly predictive of outcome in humans. Based on these promising results, CMX001 may have potential for use -- either alone or in combination - in the treatment of herpes encephalitis, neonatal herpes, or other severe HSV infections in humans."